Announcements Trials

Browse Landscape Eligibility

Clinical Trials

2 trials

Recent Start date Enrollment

OTHER_GOV × Pathologic Complete Response × pertuzumab × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Withdrawn 1 Recruiting 1

Sponsor Class

OTHER_GOV 2 OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Conditions

Breast Neoplasms 4 Pathologic Complete Response 2

Interventions

pertuzumab 2 Trastuzumab 2 Docetaxel 2 Carboplatin 2 Epirubicin 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06927180 2025-06-23

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Henan Cancer Hospital

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms

NCT05474690 2024-02-26

A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Henan Cancer Hospital

Phase 3 Withdrawn

Pathologic Complete Response, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡